KEDA
KEDA Tetrapeptide | Liver Bioregulator
DoseGear research brief
Livagen is a Khavinson bioregulator tetrapeptide (KEDA) with significant hepatoprotective and immunomodulatory properties. Structurally similar to Epitalon, it normalizes immune and antioxidant status while restoring liver function in hepatitis conditions. Livagen is best known for its ability to decondense chromatin, activating silent genes including ribosomal genes to boost protein synthesis and cellular activity. Maximum protective effects occur during aging.
Livagen works through direct effects on DNA structure and function. It decondenses chromatin (tightly packed DNA), increasing expression of certain genes and improving the 'youthful' profile of cells. The peptide activates multiple genes in lymphocytes, including previously silent ribosomal genes, boosting protein synthesis and cell activity. It exhibits hepatoprotective effects through normalizing immune and antioxidant status in liver tissue.
Compound background
Study windows describe what researchers measured, not when an individual should expect a result.
Synthetic short peptide associated with Khavinson liver-bioregulator research.
Experimental hepatic and chromatin regulation through proposed gene-expression effects.
Not reported in the reviewed compound-specific evidence.
Reference data
Not personalized dosing instructions
Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.
| Research context | Amount | Frequency | Route |
|---|---|---|---|
| Chart reference | 500 mcg | Daily · See source guide | Injectable · 20 mg lyophilized vial + 3 mL BAC Water |
Reference cycle
10-20 days
Reference storage
Injectable reconstituted: 2-8°C refrigerated
Influence of KEDA Tetrapeptide on Organism Physiological Function
Effects of Livagen Peptide on Chromatin Activation in Lymphocytes from Old People
Hepatoprotective Properties of KEDA in Hepatitis Models
Khavinson Peptide Bioregulators
This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.
